ZA975077B - Modulation of LC132 (opioid-like) receptor function. - Google Patents

Modulation of LC132 (opioid-like) receptor function.

Info

Publication number
ZA975077B
ZA975077B ZA9705077A ZA975077A ZA975077B ZA 975077 B ZA975077 B ZA 975077B ZA 9705077 A ZA9705077 A ZA 9705077A ZA 975077 A ZA975077 A ZA 975077A ZA 975077 B ZA975077 B ZA 975077B
Authority
ZA
South Africa
Prior art keywords
opioid
modulation
receptor function
receptor
function
Prior art date
Application number
ZA9705077A
Other languages
English (en)
Inventor
Olivier Civelli
James Richard Martin
Frederick Monsma
Jean-Luc Moreau
Hans-Peter Nothacker
Rainer Reinscheld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA975077B publication Critical patent/ZA975077B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA9705077A 1996-06-13 1997-06-09 Modulation of LC132 (opioid-like) receptor function. ZA975077B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96109462 1996-06-13

Publications (1)

Publication Number Publication Date
ZA975077B true ZA975077B (en) 1997-12-15

Family

ID=8222893

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705077A ZA975077B (en) 1996-06-13 1997-06-09 Modulation of LC132 (opioid-like) receptor function.

Country Status (17)

Country Link
US (2) US6326156B1 (ja)
JP (1) JP3212537B2 (ja)
KR (1) KR100247670B1 (ja)
CN (1) CN1184254A (ja)
AR (1) AR007548A1 (ja)
AU (1) AU719519B2 (ja)
BR (1) BR9703546A (ja)
CA (1) CA2206192A1 (ja)
CZ (1) CZ179597A3 (ja)
HU (1) HUP9701032A3 (ja)
IL (1) IL121017A0 (ja)
MX (1) MX9704352A (ja)
NO (1) NO972707L (ja)
NZ (1) NZ328033A (ja)
PL (1) PL320527A1 (ja)
TR (1) TR199700482A2 (ja)
ZA (1) ZA975077B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010267B1 (ru) * 2002-10-07 2008-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Модуляция тревоги через блокаду гидролиза анандамида
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CA2674359A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
US9187413B2 (en) 2010-07-28 2015-11-17 The Regents Of The University Of California Peripherally restricted FAAH inhibitors
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
US6096513A (en) 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
CA2229202C (en) 1995-08-15 2008-05-20 Universite Libre De Bruxells Methods for identifying antagonist or agonist to human opioid receptor-like 1 "orl1"

Also Published As

Publication number Publication date
US6326156B1 (en) 2001-12-04
CN1184254A (zh) 1998-06-10
MX9704352A (es) 1997-12-31
AR007548A1 (es) 1999-11-10
US20020082213A1 (en) 2002-06-27
CA2206192A1 (en) 1997-12-13
KR980003586A (ko) 1998-03-30
AU2485397A (en) 1997-12-18
IL121017A0 (en) 1997-11-20
TR199700482A2 (xx) 1998-01-21
NO972707L (no) 1997-12-15
PL320527A1 (en) 1997-12-22
BR9703546A (pt) 1998-09-29
CZ179597A3 (cs) 1998-03-18
NZ328033A (en) 1998-11-25
JPH1068724A (ja) 1998-03-10
HUP9701032A3 (en) 2000-04-28
HU9701032D0 (en) 1997-07-28
NO972707D0 (no) 1997-06-12
KR100247670B1 (ko) 2000-06-01
JP3212537B2 (ja) 2001-09-25
HUP9701032A2 (hu) 1998-08-28
AU719519B2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
IL120027A0 (en) Carrier
AU3060097A (en) Java printer
AU2237297A (en) Harness
ZA978889B (en) New combination of steroids.
ZA975077B (en) Modulation of LC132 (opioid-like) receptor function.
GB2321808B (en) Single sideband modulators
AU3900497A (en) Latching system
ZA971997B (en) Resolution of threo-methylphenidate.
GB9619724D0 (en) Catalyst
GB9626130D0 (en) Improved doctor assembly
AUPO039696A0 (en) Improved anchoring system
ZA9710860B (en) Adhesives.
AU6955498A (en) Rearpoint securement system
ZA978475B (en) Sulphide containing peptides.
AU133050S (en) Carrier
HUP9700601A3 (en) Gasholder
GB2320149B (en) Modulators
AU3019197A (en) Improved anchoring system
CA79530S (en) Carrier
GB9608274D0 (en) Multicarrier modulation
ZA977131B (en) Stirring member.
GB9611953D0 (en) Discrete multi tone modulation systems
ZA977691B (en) Carrier.
TW348880U (en) Note modulation apparatus
GB9606707D0 (en) Phospatase modulator